Results 11 to 20 of about 56,186 (320)

A REGENERATIVE APPROACH TO AN ACUTE EXACERBATION OF HIP PAIN FROM AROMATASE INHIBITOR ASSOCIATED MUSCULOSKELETAL SYNDROME AND AROMATASE-INHIBITOR ARTHRALGIAS

Journal of Cancer Rehabilitation, 2022
Background Despite aromatase inhibitors (AIs) promising outcomes in breast cancer treatment, aromatase inhibitor-associated musculoskeletal syndromes (AIMSS) and aromatase inhibitor arthralgias (AIAs) are common side effects, due to the hypoestrogenic ...
Christian Vangeison, Colton Reeh, Daniel Briggi, Royce Copeland, George Polson, Emanuel N. Husu   +5 more
doaj   +1 more source

Preparation of a novel antiserum to aromatase with high affinity and specificity: Its clinicopathological significance on breast cancer tissue. [PDF]

PLoS ONE, 2017
Aromatase inhibitors have been widely used for the endocrine treatment of estrogen-dependent breast cancer in postmenopausal patients. However, clinicopathological studies of aromatase have been limited due to unsatisfactory specificity and/or restricted
Naoki Kanomata, Shiro Matsuura, Tsunehisa Nomura, Junichi Kurebayashi, Taisuke Mori, Jo Kitawaki, Takuya Moriya   +6 more
doaj   +1 more source

Shear wave elastography detects novel imaging biomarkers of aromatase inhibitor–induced joint pain: a pilot study

Journal of Ultrasonography, 2021
Aim: To determine whether differences in joint and tendon stiffness as measured by ultrasound shear wave elastography are present in breast cancer patients with aromatase inhibitor-associated arthralgias compared to age-comparable healthy control women ...
Martinez Jessica A., Taljanovic Mihra S., Witte Russell S., Nuncio Zuniga Andres A., Wertheim Betsy C., Kwoh C. Kent, Goldstein Brian A., Roe Denise J., Chalasani Pavani   +8 more
doaj   +1 more source

A case series of triplet anti-hormonal therapy in androgen receptor-positive recurrent adult ovarian granulosa cell tumor

Gynecologic Oncology Reports, 2022
Therapeutic options for recurrent adult granulosa cell tumors (AGCT) are limited. After examining the hormonal pathways involved in FOXL2-mutated granulosa cell tumor development, a novel treatment regimen was utilized for recurrent AGCT: a combination ...
Rebekah M. Summey, Janet S. Rader, Michelle Moh, William Bradley, Denise Uyar, Erin Bishop, Lindsey McAlarnen, Elizabeth Hopp   +7 more
doaj   +1 more source

Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events

Dermatology and Therapy, 2020
Anastrozole is an aromatase inhibitor. Anastrozole competitively inhibits the aromatase enzyme, which synthesizes estrogen. It is used for estrogen receptor-positive breast cancers.
Yoo Jung Kim, Philip R. Cohen
doaj   +1 more source

Aromatase expression increases the survival and malignancy of estrogen receptor positive breast cancer cells. [PDF]

PLoS ONE, 2015
In postmenopausal women, local estrogen produced by adipose stromal cells in the breast is believed to support estrogen receptor alpha (ERα) positive breast cancer cell survival and growth.
Keya De Mukhopadhyay, Zhao Liu, Abhik Bandyopadhyay, Nameer B Kirma, Rajeshwar R Tekmal, Shui Wang, Lu-Zhe Sun   +6 more
doaj   +1 more source

Virtual Screening for Identification of Dual Inhibitors against CDK4/6 and Aromatase Enzyme

Molecules, 2023
CDK4/6 and aromatase are prominent targets for breast cancer drug discovery and are involved in abnormal cell proliferation and growth. Although aromatase inhibitors have proven to be effective (for example exemestane, anastrozole, letrozole), resistance
Tenzin Adon, Dhivya Shanmugarajan, Hissana Ather, Shaik Mohammad Asif Ansari, Umme Hani, SubbaRao V. Madhunapantula, Yogish Kumar Honnavalli   +6 more
doaj   +1 more source

Long‐term prognosis is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status

BJS (British Journal of Surgery), EarlyView., 2020
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund, F. Celebioglu, T. Hatschek, J. Frisell, J. de Boniface   +4 more
wiley   +1 more source

Epitope characterization of an aromatase monoclonal antibody suitable for the assessment of intratumoral aromatase activity. [PDF]

PLoS ONE, 2009
Immunohistochemistry is one of the most suitable methods for the detection of intratumoral aromatase in order to identify patients who may respond to aromatase inhibitor therapy in hormone-dependent breast cancer.
Yanyan Hong, Hongzhi Li, Jingjing Ye, Yasuhiro Miki, Yate-Ching Yuan, Hironobu Sasano, Dean B Evans, Shiuan Chen   +7 more
doaj   +1 more source

Sex-dependent influence of endogenous estrogen in pulmonary hypertension [PDF]

, 2014
Rationale: The incidence of pulmonary arterial hypertension (PAH) is greater in women suggesting estrogens may play a role in the disease pathogenesis. Experimentally, in males exogenously administered estrogen can protect against PH; however in models ...
Audrey F. Wright, David J. Rowlands, Dukes M, Girerd B, Josephine Fullerton, Kirsty M. Mair, Lynn Loughlin, Margaret Nilsen, Margaret R. MacLean, Martin J. Hussey, Matthew Thomas, Muxfeldt ES, Nicholas Duggan, Popovic RM, Silber DH, Sonia Roberts, Takahashi H, Teichmann J   +17 more
core   +1 more source